代表性论著、科研获奖、人才称号 |
[1]. Wang N, Wang Y, Yang Y, Dong L, Zhao Y. Binding of Epimedium Flavonoids to Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies. Iran J Pharm Res. 2026 Aug 11;25(1):e172525. [2]. Wang N, Zhang KH, Xie J, Zhang L, Wang HT, Yang X, Zhao Y. Molecular interactions of icariin and icariside II with human serum albumin: a spectroscopic and molecular docking analysis. Nat Prod Res. 2025, 39(20): 5985-5993. [3]. Yi Zhao, Zelin Li, Kanghuai Zhang & Na Wang*. Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024, (12):1513-1519. [4]. Yi Zhao, Zelin Li, Kanghuai Zhang & Na Wang*. Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. Expert Opin Drug Saf. 2024 Aug; 23(8):1041-1048. [5]. Jiao Xie, Kanghuai Zhang, Haitao Wang, Xin Yang, Wenbin Mao, Chenwei Liu, Na Wang*. Determination of the Solubility, Dissolution Enthalpy, and Entropy of Icariin in Acetone, Acetoacetate, Chloroform, and Light Petroleum, Natural Product Communications, 2020, 15(11): 1-6. |